Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PECS II block with liposomal bupivacaine versus levobupivacaine for mastectomy pain control
NL-OMON53831Phase 3Recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Oct 2023
- Modality
- Small Molecules, Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in postoperative pain comparing PECS II block with liposomal bupivacaine with PECS II block with levobupivacaine (2 arms). Primary endpoint: Postoperative NRS pain scores over the first 72 hours. Started Oct 2023; status: recruiting.
02
Drugs
liposomal bupivacainelevobupivacaine
03
Conditions
postoperative pain
Beyond the preview
Go deeper on NL-OMON53831.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53831.